S-1/A: Healthcare Software Firm Faces Delisting Threat Amidst Deepening Losses and Extensive Dilution

A healthcare software company is seeking to register millions of shares for public and secondary offerings while grappling with significant financial losses, a going concern warning, and multiple Nasdaq listing deficiencies.

Summary

• The company is registering up to 11,500,000 shares of common stock for primary issuance upon exercise of Public Warrants and up to 28,152,560 shares for secondary resale by selling securityholders.
• Reported a net loss of $1.9 million for the three months ended March 31, 2025, compared to $2.1 million for the same period in 2024.
• Full-year net losses were $10.1 million for 2024 and $33.8 million for 2023, with an accumulated deficit of $103.5 million as of March 31, 2025.
• Total revenue decreased by 45% to $137,000 for Q1 2025, primarily due to a 71% decrease in subscription revenue from the planned discontinuation of the BEAM platform.
• Web imaging revenue (iRWD) increased by 68% to $79,000 for Q1 2025, reflecting an enhanced focus on this segment.
• The company's independent auditors have expressed substantial doubt about its ability to continue as a going concern.
• Received notices from Nasdaq on March 12, 2025, for non-compliance with minimum market value of listed securities ($35 million), minimum stockholders' equity ($2.5 million), and minimum net income ($500,000) requirements.
• Received a separate notice from Nasdaq on April 10, 2025, for non-compliance with the $1.00 minimum bid price requirement.
• Successfully settled or converted approximately $11.0 million of current liabilities in Q2 2025, representing a 60% reduction in total liabilities outstanding as of March 31, 2025, through various debt-to-equity conversions and settlements.
• Engaged in several private placements in 2024 and 2025, raising aggregate gross proceeds of approximately $4.6 million (July 2024), $1.7 million (September 2024), $2.5 million (June 2025), and $1.2 million (June 2025).
• Invested in Bitcoin using net proceeds from private placements, holding $793,000 in Bitcoin as of March 31, 2025, and realizing a gain of $531,000 on Bitcoin sales in Q1 2025.

Sentiment

Score: 2

Explanation: The company faces severe financial challenges, including recurring losses, a going concern warning, and multiple Nasdaq listing deficiencies. While recent debt conversions and capital raises provide some short-term relief, the underlying business performance and market conditions suggest a highly precarious situation.

Positives

• Web imaging revenue (iRWD) increased by 68% for the three months ended March 31, 2025, indicating growth in the company's strategic focus area.
• Successfully settled or converted approximately $11.0 million of current liabilities in Q2 2025, reducing total liabilities by 60% as of March 31, 2025, which improves the balance sheet.
• Secured significant capital through multiple private placements and a Standby Equity Purchase Agreement (SEPA) with Yorkville, providing potential funding for operations.
• Realized a gain of $531,000 on the sale of crypto assets (Bitcoin) during the three months ended March 31, 2025.

Negatives

• Reported a net loss of $1.9 million for Q1 2025 and an accumulated deficit of $103.5 million as of March 31, 2025, indicating a history of operating losses.
• Overall revenue decreased by 45% for Q1 2025, primarily driven by a 71% decrease in subscription revenue due to the planned discontinuation of the BEAM platform.
• Cost of revenue as a percentage of revenue significantly increased to 264% in Q1 2025 from 128% in Q1 2024, indicating worsening gross margins.
• The company's cash and Bitcoin balance of $144,000 and $793,000, respectively, as of March 31, 2025, is deemed insufficient to fund operations for at least the next 12 months.
• Independent auditors have expressed substantial doubt about the company's ability to continue as a going concern.
• Received multiple Nasdaq notices for non-compliance with listing requirements, including minimum market value of listed securities ($35 million), minimum stockholders' equity ($2.5 million), minimum net income ($500,000), and minimum bid price ($1.00).
• The current market price of common stock ($0.607 as of July 10, 2025) is significantly below the Public Warrant exercise price ($11.50), making warrant exercise unlikely and limiting potential cash proceeds from primary offering.
• Private investors have an incentive to sell shares even at current low prices due to their lower purchase prices, potentially leading to further dilution and downward pressure on the stock price.
• Identified material weaknesses in internal control over financial reporting related to user access/segregation of duties, lack of formalized control environment, accounting for non-routine transactions, and record keeping.

Risks

• The common stock may be subject to extreme volatility due to various factors including operating results, competitor actions, changes in market expectations, and general economic conditions.
• Inability to maintain listing on the Nasdaq Capital Market or any other stock exchange could adversely affect stock price, liquidity, and ability to obtain financing.
• Principal stockholders will continue to have significant influence over corporate actions, potentially delaying or preventing acquisitions.
• Risk of securities class action litigation, which could result in substantial costs and diversion of management attention.
• No expectation of paying dividends in the foreseeable future, requiring investors to rely on price appreciation for returns.
• Future sales of substantial amounts of common stock or convertible securities could adversely affect the market price due to dilution.
• The company has a history of operating losses and may never achieve profitability.
• Difficulties in managing business growth could negatively impact operations.
• Inability to successfully execute business objectives and growth strategies or sustain growth could materially adversely affect operating results.
• The Real World Data and Real World Evidence market is highly competitive, and the company may not succeed in establishing confidence among partners and customers.
• Inability to attract and retain key employees and qualified personnel could harm competitiveness.
• Material breaches in security, cyber-attacks, or other disruptions to information systems could expose the company to liability and affect business and reputation.
• Failure to adequately protect or expand intellectual property could harm business prospects.
• Failure to comply with extensive legal and regulatory requirements in the healthcare industry could lead to increased costs, penalties, and loss of business.
• Collection, use, and disclosure of personal information are subject to privacy and security regulations, and non-compliance could result in significant liability or reputational harm.
• Operations could be adversely affected by natural disasters and other catastrophic events, with potentially inadequate insurance coverage.
• Ability to utilize net operating loss and tax credit carryforwards may be subject to limitations due to ownership changes.
• Risks related to holding Bitcoin, including high volatility, regulatory uncertainty, and lack of FDIC/SIPC protection.
• Management has limited experience in operating a public company, potentially leading to increased expenses and administrative burdens.
• Material weaknesses in internal control over financial reporting could lead to inaccurate or untimely financial reporting and adversely affect the business.
• The business model is capital-intensive, and inability to raise additional capital on attractive terms could materially and adversely affect operations and prospects.
• The company may redeem unexpired Public Warrants prior to their exercise at a disadvantageous time for holders, especially if the stock price is below the exercise price.

Future Outlook

The company intends to continue funding operations through equity and debt financing arrangements, aiming to achieve profitable operations. Its long-term growth strategy focuses on increasing global reach in the Real World Evidence solutions market, innovating its commercial approach by expanding sales networks and focusing on Imaging AI, medical device, and pharmaceutical target markets, and continually enhancing and refining its service offering, including expanding its product portfolio into other high-growth, high-demand Real World Data and Real World Evidence solutions.

Management Comments

• Management does not believe that current cash and cash equivalents are sufficient to meet foreseeable cash needs for at least the next 12 months.
• Management plans to raise additional working capital through equity and debt offerings to fund operations and capital requirements.
• Management is presently evaluating potential actions to regain compliance with all applicable requirements for continued listing on the Nasdaq Capital Market.
• Management determined that, as of December 31, 2024, the company did not maintain effective internal control over financial reporting and is in the process of remediation.

Industry Context

The company operates in the evolving and highly competitive Real World Data (RWD) and Real World Evidence (RWE) market, focusing on digital medical image management and curation. This market is driven by increasing demand for enhanced RWE capabilities within the life science industry, a shift from volume to value-based care, and regulatory support from agencies like the FDA for RWD/RWE in drug development and approvals. The company aims to leverage its federated provider network and AI/ML technology to meet the rigorous demands of life science companies, particularly in oncology and other therapeutic areas where RWE is increasingly relied upon.

Comparison to Industry Standards

• The global Real World Evidence solutions market size was estimated at $2.6 billion in 2023 and is expected to grow at a CAGR of 8.4% from 2024 to 2030, indicating a growing market that the company is targeting.
• The global Real World Data market is estimated to be valued at $7.51 billion in 2024 and is expected to exhibit a CAGR of 9.1% during 2024-2031, suggesting significant market opportunity for the company's iRWD solution.
• The company's focus on regulatory-grade imaging RWD that matches life science partners' case selection protocols aligns with FDA guidelines for regulatory approvals, which increasingly utilize RWD to supplement or supplant clinical trials.
• The company's use of AI/ML technology for data anomaly detection, standardization, and quality checking in RWD curation is consistent with industry trends where AI is expected to increase meaningful RWE output and decrease time to insights for pharma and biotech companies.
• The company's claim of having access to more than 1,400 healthcare sites and covering over 31 million patient records positions it as a significant player in compiling imaging RWD, which is a competitive advantage in a fragmented data landscape.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not presently party to any legal proceedings that, in the opinion of management, would individually or taken together have a material adverse effect on its business, operating results, financial condition, or cash flows.

Related Party Transactions

• PIPE Notes and Warrants: $1.0 million of the $1.5 million PIPE Notes and 63,829 of the 95,744 PIPE Warrants were issued to related party investors, including the CEO, Chairman, and a director.
• Convertible Promissory Notes and Warrants: $12.3 million (out of $14.2 million total) of Convertible Promissory Notes and 2,976,000 (out of 3,726,000 total) Convertible Promissory Note Warrants were issued to related party investors from 2019-2023.
• Shareholder Loans: Received $954,000 in shareholder loans from Dr. Yu and Dr. Kosasa from April-December 2023, and an additional $2.0 million in 2024, of which $1.6 million is convertible into common stock.
• Loan Extensions: Assumed $3.0 million in existing loan extensions to related parties from Data Knights liabilities, which are outstanding as of March 31, 2025.
• Other Private Placements: Dr. Thomas Kosasa and Dr. Jeffrey Yu participated in separate private placements on June 20, 2025, investing $500,000 and $700,000 respectively, for common stock at $0.42 per share.
• Debt Reductions: On June 19, 2025, Dr. Kosasa and Dr. Yu converted approximately $3.3 million of outstanding loans and accrued interest into 4,693,296 shares of common stock. Dr. Kosasa also converted $1.6 million of convertible shareholder loans into 2,123,424 shares.

Stakeholder Impact

• Shareholders face significant dilution from the registration of up to 39.65 million shares for primary issuance and secondary resale, representing a substantial percentage of outstanding common stock.
• Public shareholders may experience a negative rate of return due to the current trading price ($0.607) being significantly below the initial public offering price of Data Knights ($10.00) and the Public Warrant exercise price ($11.50).
• Private investors, including related parties, may still profit on sales due to their lower purchase prices, creating a potential conflict of interest and further downward pressure on the stock.
• Employees and management are affected by executive turnover and changes in compensation structures, including stock-based awards.
• Customers of the BEAM platform will be impacted by its planned discontinuation, while iRWD customers may benefit from enhanced focus and increased deliveries.
• Creditors involved in the recent debt settlements and conversions will see their liabilities transformed into equity or cash, impacting their risk exposure and potential returns.

Next Steps

• Regain compliance with Nasdaq listing requirements by September 8, 2025, for MVLS, stockholders' equity, and net income.
• Regain compliance with Nasdaq's $1.00 minimum bid price requirement by October 7, 2025, potentially through a reverse stock split.
• Continue efforts to raise additional working capital through equity and debt offerings.
• Remediate identified material weaknesses in internal control over financial reporting.
• Continue to focus on and expand iRWD sales to drive revenue growth.

Key Dates

Recommendation

Keywords

Real World Data, Real World Evidence, Medical Imaging, Healthcare IT, Digital Health, S-1/A, SEC Filing, Nasdaq Compliance, Going Concern, Private Placement, Warrants, Convertible Notes, Biotechnology, Pharmaceutical, Medical Device, AI in Healthcare, Data Curation, HIPAA, Cybersecurity